TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Average Recommendation of “Buy” by Brokerages

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has earned a consensus rating of “Buy” from the nine brokerages that are covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $10.93.

TLSI has been the subject of several recent analyst reports. Lake Street Capital initiated coverage on shares of TriSalus Life Sciences in a report on Thursday, February 13th. They set a “buy” rating and a $10.00 price objective for the company. Roth Mkm reaffirmed a “buy” rating and set a $11.00 price objective on shares of TriSalus Life Sciences in a report on Friday, January 24th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $11.00 price objective on shares of TriSalus Life Sciences in a report on Friday, March 28th.

TriSalus Life Sciences Trading Down 0.8%

NASDAQ TLSI opened at $5.07 on Wednesday. The company has a fifty day simple moving average of $5.40 and a 200 day simple moving average of $4.98. The company has a market cap of $163.62 million, a P/E ratio of -2.04 and a beta of 0.50. TriSalus Life Sciences has a 1 year low of $3.50 and a 1 year high of $10.24.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.35). The firm had revenue of $8.26 million for the quarter, compared to the consensus estimate of $8.12 million. Equities research analysts forecast that TriSalus Life Sciences will post -1.55 EPS for the current fiscal year.

Institutional Trading of TriSalus Life Sciences

A number of hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its holdings in TriSalus Life Sciences by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 204,137 shares of the company’s stock valued at $1,023,000 after purchasing an additional 3,710 shares during the period. Bank of America Corp DE boosted its holdings in TriSalus Life Sciences by 120,471.6% in the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company’s stock valued at $894,000 after purchasing an additional 178,298 shares during the period. Bridgeway Capital Management LLC boosted its holdings in TriSalus Life Sciences by 333.3% in the 4th quarter. Bridgeway Capital Management LLC now owns 65,000 shares of the company’s stock valued at $326,000 after purchasing an additional 50,000 shares during the period. Northern Trust Corp lifted its holdings in shares of TriSalus Life Sciences by 22.7% during the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company’s stock worth $161,000 after acquiring an additional 5,936 shares during the period. Finally, Connective Capital Management LLC bought a new position in shares of TriSalus Life Sciences during the 4th quarter worth about $140,000. 2.58% of the stock is owned by institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.